NCT06815679 - Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2026

Conditions

Acute Respiratory FailurePneumonia

Interventions

DRUG

salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)

To evaluate the patient's respiratory effort, the pressure-time product (PTPes) and the delta of Pes oscillations during inspiration (∆ Pes) will be obtained from the analysis of the Pes curve. Global and regional pulmonary tidal volumes will be evaluated with Electrical Impedance Tomography

Trial Locations (1)

44121

Azienda ospedaliera Universitaria di Ferrara, Ferrara